Evestra, Inc. today
announces the signing of a collaboration partnership agreement with the
Hungarian company, Gedeon Richter Plc. Under the terms of the agreement,
Evestra will perform certain research and development activities on
contraceptive products in exchange for licensing the commercialization rights
for certain territories outside the US to Gedeon Richter Plc.
The deal consists of upfront payments
for research and early development funding, as well as clinical development,
regulatory and sales performance milestones, and royalty payments on net sales.
announced today that its first patent in the antiprogestin area which
describes new chemical entities with
potential applications in oncology and gynecological indications was allowed by
the US patent Office. The description of
these compounds and their properties was published in a recent paper in the
Evestra is excited to announce that, effective January 15,
2014, we will be relocated to our new facilities at 14805 Omicron Drive, Suite
100, San Antonio, Texas, 78245. Current company phone number will remain
the same, 210-673-3300.
The new facilities include state-of-the-art chemistry
laboratory space, as well as a Good Manufacturing Practices (GMP) facility,
biological laboratory to conduct in vitro biological characterization of new
chemical entities, and a analytical development and quality control (QC)
laboratory. The new facility will enable Evestra to fully and efficiently
develop its product pipeline, including unmet medical needs in women’s health.